Skip Navigation

Nephrology Dialysis Transplantation 2008 23(11):i; doi:10.1093/ndt/gfn568
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


In This Issue

The first 10% of the full text of this article appears below.

Drug monitoring of mycophenolic acid (MPA) is not frequently applied in patients with autoimmune diseases. An interesting clinical study and accompanying editorial comment discuss this issue. The study showed that prevention of recurrence of disease was associated with higher trough levels (>3.0 mg/L), but that adverse events were clustered in patients with high MPA exposure.

See editorial comment by de Winter and van Gelder, pages 3386–3388 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?